Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264090 | 0.94 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL711832 | 0.75 | ATM (0.34) | — | |
| SCHEMBL20303735 | 0.73 | OPRK1 (0.32) | — | |
| SCHEMBL9610 | 0.73 | ATM (0.33) | — | |
| SCHEMBL15720686 | 0.71 | HTR2C (0.31) | — | |
| SCHEMBL15046910 | 0.71 | — | — | |
| SCHEMBL16984972 | 0.70 | HRH3 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL26046565 | 0.70 | HRH3 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL11787362 | 0.70 | OPRK1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL30269648 | 0.69 | HRH3 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2016189304-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2016-12-01 | — | — | WO | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| WO-2002069895-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001092226-A1 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF | SEPRACOR, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | CHRNB2 261/4885CHRNA4 186/4885CHRNB4 280/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | CHRNB2 261/4885CHRNA4 186/4885CHRNB4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.